Abstract:The review is focused on recent drug discovery advances based on targeted protein degradation strategies. This new area of research has exploded leading to the development of potential drugs useful in a large variety of human diseases. They first target disease relevant proteins difficult to counteract with other classical strategies and extend now to aggregates, organelles, nucleic acids or lipidic droplets. These degraders engaged either the ubiquitin-proteasome system for PROTACs and molecular glues (first generation), or the lysosomal system via endosome-lysosome degradation (LYTACs) and autophagy-lysosome degradation (ATTEC, AUTAC, AUTOTAC) (following generations of degraders). PROTACs have expanded from the orthodox heterobifunctional ones to new derivatives such as homo-PROTACs, pro-PROTACs, CLIPTACs, HaloPROTACs, PHOTOTACs, Bac-PROTACs, AbTACs, ARN-PROTACs. The small molecular-weight molecular glues induce the formation of new ternary complexes which implicate the targeted protein and an ubiquitin ligase E3 allowing the protein ubiquinitation followed by its proteasomal degradation. Lysosomal degraders (LYTAC, ATTEC, AUTAC, AUTOTAC) specifically recognize extracellular and membrane proteins or dysfunctional organelles and transport them into lysosomes where they are degraded. They overcome the limitations observed with proteasomal degradations induced by PROTAC and molecular glues and demonstrate their potential to treat human diseases, especially neurodegenerative ones. Pharmaceutical companies are engaged at the world level to develop these new potential drugs targeting cancers, immuno-inflammatory and neurodegenerative diseases as well as a variety of other ones. Efficiency and risks for these novel therapeutic strategies are discussed.

Synthetic modification of protein surfaces to mediate induced-proximity pharmacology

Proximity-Based Modalities for Biology and Medicine

Chemically induced proximity in biology and medicine

Site-selective protein modification via peptide-directed proximity catalysis

Target Bioconjugation of Protein Through Chemical, Molecular Dynamics, and Artificial Intelligence Approaches

Bifunctional modalities for repurposing protein function

Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications

Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics

Recent Advances towards the Reversible Chemical Modification of Proteins

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Leveraging Covalency to Stabilize Ternary Complex Formation For Cell-Cell "Induced Proximity"

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Automated Flow Peptide Synthesis Enables Engineering of Proteins with Stabilized Transient Binding Pockets

Targeting protein-ligand neosurfaces using a generalizable deep learning approach

Chemical modification of proteins by insertion of synthetic peptides using tandem protein trans-splicing

Harmony of Protein Tags and Chimeric Molecules Empowers Targeted Protein Ubiquitination and Beyond

Proximity‐Enabled Protein Crosslinking Through Genetically Encoding Haloalkane Unnatural Amino Acids

Switchable DNA Catalysts for Proximity Labeling at Sites of Protein-Protein Interactions

Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors

Molecular Glues For Targeted Protein Degradation: From Serendipity To Rational Discovery

Using Protein-Confined Proximity To Determine Chemical Reactivity